[HTML][HTML] Resistance to hypomethylating agents in myelodysplastic syndrome and acute myeloid leukemia from clinical data and molecular mechanism
G Zhao, Q Wang, S Li, X Wang - Frontiers in Oncology, 2021 - frontiersin.org
The nucleoside analogs decitabine (5-AZA-dC) and azacitidine (5-AZA) have been
developed as targeted therapies to reverse DNA methylation in different cancer types, and …
developed as targeted therapies to reverse DNA methylation in different cancer types, and …
Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies
PG Woost, BM William, BW Cooper… - Cytometry Part B …, 2024 - Wiley Online Library
Abstract The 5‐azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation‐
inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid …
inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid …
Demethylating agents in myeloid malignancies
G Garcia-Manero - Current opinion in oncology, 2008 - journals.lww.com
Demethylating agents in myeloid malignancies : Current Opinion in Oncology
Demethylating agents in myeloid malignancies : Current Opinion in Oncology Log in or …
Demethylating agents in myeloid malignancies : Current Opinion in Oncology Log in or …
Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings
N Uy, A Singh, SD Gore, T Prebet - Expert opinion on …, 2017 - Taylor & Francis
Introduction: Hypomethylating agents (HMA) have played a pivotal role for treating
myelodysplastic syndromes (MDS) over the past decade, inducing sustained hematological …
myelodysplastic syndromes (MDS) over the past decade, inducing sustained hematological …
Concise drug review: azacitidine and decitabine
EJB Derissen, JH Beijnen, JHM Schellens - The oncologist, 2013 - academic.oup.com
The introduction of the hypomethylating agents azacitidine and decitabine has been a major
advancement in the treatment of patients with higher‐risk myelodysplastic syndromes …
advancement in the treatment of patients with higher‐risk myelodysplastic syndromes …
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)
First-line therapy for higher-risk myelodysplastic syndromes (MDS) includes decitabine
(DAC) or azacitidine (AZA). Variables have not identified differential response rates between …
(DAC) or azacitidine (AZA). Variables have not identified differential response rates between …
[HTML][HTML] A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines
PW Hollenbach, AN Nguyen, H Brady, M Williams… - PloS one, 2010 - journals.plos.org
Background The cytidine nucleoside analogs azacitidine (AZA) and decitabine (DAC) are
used for the treatment of patients with myelodysplastic syndromes and acute myeloid …
used for the treatment of patients with myelodysplastic syndromes and acute myeloid …
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
E Jabbour, NJ Short, G Montalban-Bravo… - Blood, The Journal …, 2017 - ashpublications.org
Hypomethylating agents (HMAs) improve survival in patients with higher-risk
myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We …
myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We …
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors
LA Cowan, S Talwar, AS Yang - Epigenomics, 2010 - Taylor & Francis
The recent approval of azacitidine (Vidaza®), decitabine (Dacogen®) and vorinostat
(Zolinza™) for myelodysplastic syndrome and cutaneous T-cell lymphoma has led to a wave …
(Zolinza™) for myelodysplastic syndrome and cutaneous T-cell lymphoma has led to a wave …